Company intelligence / Profile preview

Ariston Pharmaceuticals

Framingham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Ariston Pharmaceuticals was a clinical-stage biotechnology company focused on neurology and CNS disorders. Its lead candidate, AST-915 (propranolol hydrochloride), completed Phase 2 clinical trials for the treatment of essential tremor. Another lead candidate, AST-726, an intranasal spray formulation, successfully completed Phase 2 trials for Vitamin B12 deficiency, demonstrating that therapeutic levels of Vitamin B12 could be delivered effectively via the nasal mucosa. The company was acquired in 2010, and its programs were largely discontinued thereafter.

Therapeutic areas: HematologyNeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

National Institutes of Health (NIH)

Beyond the preview

Go deeper on Ariston Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ariston Pharmaceuticals.

Explore the full profile